Sygnature drug discovery acquisition to strengthen field

Sygnature Discovery, which claims to be the UK’s largest independent drug discovery expert and research partner, revealed that it has acquired Scotland-based SB Drug Discovery, a provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.

This transaction, financial terms of which were not disclosed, will offer a strategic advantage for both companies, to enable further expansion of the businesses and their capabilities, and forms part of Sygnature’s strategic plan to continuously invest in the expansion of its leading integrated drug discovery solutions.

Fifth acquisition in five years